US 11,718,853 B2
Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
Roy C Levitt, Jr., Miami Beach, FL (US)
Assigned to ONSPIRA THERAPEUTICS, INC., Wayne, PA (US)
Filed by Onspira Therapeutics, Inc., Wayne, PA (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,835.
Application 17/366,835 is a continuation of application No. 16/714,948, filed on Dec. 16, 2019, granted, now 11,091,763.
Application 16/714,948 is a continuation of application No. 14/605,545, filed on Jan. 26, 2015, granted, now 10,550,389, issued on Feb. 4, 2020.
Application 14/605,545 is a continuation of application No. 12/377,027, granted, now 8,940,683, issued on Jan. 27, 2015, previously published as PCT/US2007/017800, filed on Aug. 10, 2007.
Claims priority of provisional application 60/907,028, filed on Mar. 16, 2007.
Claims priority of provisional application 60/878,385, filed on Jan. 4, 2007.
Claims priority of provisional application 60/836,760, filed on Aug. 10, 2006.
Prior Publication US 2021/0395748 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); C12N 15/113 (2010.01); A61K 38/20 (2006.01); A61K 31/70 (2006.01); C07K 14/715 (2006.01); A61P 11/08 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C12N 15/1136 (2013.01) [A61K 9/007 (2013.01); A61K 9/008 (2013.01); A61K 9/0075 (2013.01); A61K 9/0078 (2013.01); A61K 31/70 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 38/1793 (2013.01); A61K 38/20 (2013.01); A61K 38/2006 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 11/08 (2018.01); C07K 14/7155 (2013.01); C12N 15/113 (2013.01); C07K 2319/30 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01)] 26 Claims
 
1. A method for treating an inflammatory disorder of lower airways in a human subject in need thereof, the method comprising administering directly to the lower airways in the human subject an effective amount of anakinra, wherein the effective amount of anakinra is administered using a nebulizer.